Skip to content

Stepped care to improve depression and anxiety in cancer patients.

Cost-effectiveness of a stepped care strategy to improve symptoms of depression or anxiety in patients treated for head and neck cancer or lung cancer.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON26555
Enrollment
176
Registered
2009-06-18
Start date
2009-09-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and neck neoplasms

Interventions

Stepped care model with 4 evidence based steps: 1. Watchful waiting
2. Internet-based self-help
3. Problem Solving Therapy applied by a nurse
4. Specialised psychological interventions and/or antidepressant medication. Control group patients receive care as usual.

Sponsors

VUmc
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Treatment for UICC stage I-IV lung or head and neck carcinoma: ICD-10 C00-C14 (lip, oral cavity and pharynx), C32 (larynx), C33 (trachea), C34 (lung); 2. Depression (minor or major) or (generalized) anxiety disorder as assessed by the Composite International Diagnostic Interview (CIDI).

Exclusion criteria

Exclusion criteria: 1. Other (neurological) diseases causing cognitive dysfunction; 2. No motivation to undergo psychosocial therapy; 3. Current treatment for a depressive or anxiety disorder; 4. End of treatment for a psychiatric disorder less than two months ago; 5. High suicide risk; 6. Psychotic and/or manic signs; 7. Too little knowledge of the Dutch language to fill out the questionnaires.

Design outcomes

Primary

MeasureTime frame
Primary outcome is the Hospital Anxiety and Depression Scale (HADS).

Secondary

MeasureTime frame
Secondary outcome measures are quality of life questionnaires (EORTC QLQ-C30, EORTC QLQ-HN35, EORTC QLQ-LC13), patient satisfaction with care (EORTC QLQ-PATSAT), and costs (health care utilization and work loss (TIC-P and PRODISQ modules)).

Contacts

Public ContactI.M. Verdonck-de Leeuw

PO Box 7057

im.verdonck@vumc.nl+31(0)20-4443690

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)